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Background/objectives: To examinewhether higher fasting plasma glucose (FPG) levelswere independently asso-
ciated with left ventricular (LV) mass and/or geometry in elderly, otherwise healthy subjects.
Methods:We tested cross-sectional associations between echocardiographically determined LV mass/geometric
patterns, cardiovascular risk factors, and FPG categorized as normal fasting glucose (NFG), impaired fasting glu-
cose (IFG), and untreated diabetes mellitus (DM), in 486 men and 207 women aged 56–79 years without overt
cardiovascular disease, who received no cardiovascular, anti-diabetic, or lipid-lowering drugs and had a pre-
served LV ejection fraction N50%.
Results: Unadjusted mean LV mass index (LVMI) was signiﬁcantly greater among subjects with DM than those
without (90 +/− 26 g/m2 vs. 85 +/− 20 g/m2, p = 0.01), as were both relative wall thickness (RWT)
(0.43 +/− 0.09 vs. 0.40 +/− 0.08, p = 0.01) and prevalence of concentric LV hypertrophy (LVH) (11% vs. 6%,
p = 0.03). However, only RWT remained signiﬁcantly associated with the presence of DM after multivariable ad-
justment (p = 0.04). Interaction analyses revealed that greater LVMI/LVH was predominantly associated with
higher levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) among subjectswith IFG orDM, but notNFG.
Conclusions: Subjectswith untreated DMhad higher values of LVMI and a greater prevalence of concentric LVH, but
the associations were not independent of other risk factors. NT-proBNP was primarily associated with greater LV
size in subjects with IFG or DM.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is anopen access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Left ventricular hypertrophy (LVH) is an independent predictor of
cardiovascular morbidity and mortality in subjects both with and
without diabetes mellitus (DM) [1–3]. The increase in cardiovascular
risk is directly related to the magnitude of increase in LV mass (LVM)
[4,5]. Furthermore, the LV geometric pattern determined by the combi-
nation of LVmass index (LVMI) and relative wall thickness (RWT) may
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provide additional prognostic information beyond assessment of LVM
alone [6,7].
The pathogenesis of LVH is presumably multifactorial and driven by
both hemodynamic and non-hemodynamic factors [8–13]. LVMI and
possibly also RWT are signiﬁcantly greater among patients with DM
than those without, and the casemay be the same for subjects with im-
paired glucose tolerance (IGT) [14–20]. However, only few studies have
investigated the association between DM and LVM after adjusting for
body size and other traditional risk factors [14–19], andwhether a grad-
ed association between fasting plasma glucose (FPG) category and LVM
and geometry exists, has not been clearly established.
Given these knowledge gaps, a comprehensive evaluation of LV size
and geometry and their relation to fasting glucometabolic status is jus-
tiﬁed and may reveal putative mechanisms for the development of LVH
in subjects with impaired glucose metabolism. Therefore, the purpose
of this cross-sectional study was: 1) To examine whether worse
glucometabolic status (i.e. higher FPG category) was associated
with greater LVMI, independently of other hemodynamic and non-
hemodynamic risk factors; 2) To describe the association between FPG
category and LV geometric pattern based on LVMI and RWT; and 3) To
identify other risk factors independently associated with greater LVMI
and LV geometric pattern.
2. Methods
2.1. Study population
The study subjects were derived from theMalmö Preventive Project
(MPP, 1974–1992, n = 33,346), a population-based cohort study with
the aim of screening for cardiovascular risk factors, alcohol abuse, and
breast cancer among inhabitants of Malmö, Sweden, born 1921–1949
[21]. A re-examination study (MPP-RES, n=18,238)was conducted be-
tween 2002 and 2006, during which the participants answered a self-
administered questionnaire on lifestyle, medical history, and medica-
tion. Blood pressure and pulse rate were recorded twice in the supine
position after 5 min of rest (with the values averaged for the analyses),
and height, weight, waist and hip circumferences were measured.
Moreover, blood samples were drawn after overnight fasting for analy-
sis of plasma glucose, serum lipids, and storage in a biobank. In a sub-
sample of 1792 individuals from MPP-RES, an echocardiography and a
12-lead ECG recording were carried out. These subjects were randomly
selected from groups deﬁned by fasting plasma glucose (FPG), with
oversampling in groups of subjects with impaired fasting glucose
(IFG) and DM, in order to ensure a sufﬁcient number of individuals in
each category. Both MPP and MPP-RES were approved by the Ethics
Committee of Lund University, Sweden, and conducted in accordance
with the Declaration of Helsinki. Written informed consent was obtain-
ed from all participants.
2.2. Prevalent cardiovascular disease or diabetes mellitus
Subjects with prevalent cardiovascular disease (n = 300) and/or
those on cardiovascular (incl. antihypertensive) (n = 864), anti-
diabetic (n= 329) or lipid-lowering therapy (n= 464) were excluded
in the present study (total excluded n = 1029). Prevalent cardiovascu-
lar disease was deﬁned by the International Classiﬁcation of Diseases
(ICD-9 and ICD-10) codes gathered from the Swedish Hospital Dis-
charge Registry as well as local hospital and study registries and
encompassed previous myocardial infarction, percutaneous coronary
intervention, coronary artery bypass grafting, heart failure, stroke, or
atrial ﬁbrillation and/or ﬂutter.
2.3. Fasting plasma glucose category
The deﬁnitions of normal fasting glucose (NFG), IFG, and DM were
based on the World Health Organization (WHO) criteria [22]: NFG was
deﬁned as a single FPG ≤ 6.0 mmol/L; IFG was deﬁned as a single FPG
between 6.1–6.9 mmol/L, or one measurement 7.0–11.0 mmol/L
and a separate measurement ≤6.9 mmol/L; and untreated DM was
deﬁned as a single FPG ≥ 11.1 mmol/L or two separate measurements
≥7.0 mmol/L.
2.4. Echocardiography
Echocardiography was conducted with a 3V2c transducer (Acuson
Sequoia, Mountain View, CA) or an S3 transducer (Sonos 5500 Philips,
Andover, MA). LV ejection fraction (LVEF) was quantiﬁed visually.
LVM calculations were based on 2-dimensional linear measurements
in the parasternal long-axis view at the tips of the mitral valve leaﬂets
at end-diastole, perpendicular to the long axis of LV. The thickness of
the interventricular septum (IVS), LV internal diameter (LVID), and
the thickness of the posterior wall (PW) were obtained by placing the
calipers on the interface betweenmyocardialwall and cavity and the in-
terface between myocardial wall and pericardium, respectively. LVM
was then calculated using the Cube formula recommended by the
American Society of Echocardiography (ASE) and the European Association
of Cardiovascular Imaging (EACVI) [23], and indexed for BSA, obtaining
LVMI. Cut-off values for LVH were LVMI N95 g/m2 in women and
N115 g/m2 in men, respectively. Relative wall thickness (RWT) was cal-
culated as (2 × PW) / LVID, allowing categorization of LV geometry into
normal (normal LVMI and RWT ≤ 0.42), concentric remodeling (normal
LVMI and RWT N 0.42), eccentric LVH (increased LVMI and RWT ≤ 0.42),
and concentric LVH (increased LVMI and RWT N 0.42).
LV diastolic function was assessed in the apical four-chamber view
using transmitral pulsed Doppler ﬂow with a 1–3 mm sample volume
placed between the tips of the mitral valve leaﬂets (obtaining E, A,
and E-wave deceleration time (DT)) and tissue Doppler imaging with
the sample volume positionedwithin 1 cm of the septal and lateral bor-
ders of themitral annulus (obtaining both septal and lateral é and aver-
aging the values for the analyses). A mean of 3–5 cycles was used. The
intra- and interobserver variability is reported elsewhere [24]. Diastolic
function was graded according to the recommendations of ASE and
EACVI (formerly known as the European Association of Echocardiography)
[25], using age-appropriate cut-off values of septal é, lateral é, E-wave
DT, E/A, and averaged E/é. If septal é was ≥8 and/or lateral é was ≥10,
subjects were classiﬁed as having normal diastolic function. If septal é
wasb8 and lateral éwasb10, subjectswere classiﬁed ashavingdiastolic
dysfunction, and the values of E-wave DT, E/A, and E/é were used for
grading subjects into grade 1, 2 or 3 diastolic dysfunction (Table 1). If
E/é was ≥9 and ≤12, subjects were only classiﬁed as having either
grade 1 or 2 diastolic dysfunction if the values of both E-wave DT and
E/A ﬁtted the same category. If E/é ≥ 9 and ≤12, but E/A and E-wave
DT were incompatible with each other, subjects were classiﬁed as hav-
ing undetermined diastolic dysfunction [26]. If E/é was N12, subjects
were classiﬁed as having either grade 2 or 3 diastolic dysfunction. Final-
ly, all subjects with E/é b 9 were classiﬁed as either normal (E-wave
DT b 240 ms and E/A ≥ 0.8) or grade 1 diastolic dysfunction (all other
subjects), even if they did not strictly fulﬁll the primary é criteria for
normal diastolic function. Subjects with LVEF ≤50% were excluded
from the present study (n= 29). Moreover, 41 subjects were excluded
due tomissing echocardiographic variables. None of the remaining sub-
jects had severe left-sided valvular stenosis or regurgitation.
2.5. Biomarkers
In the echocardiography subcohort, N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) was analyzed using an electro-
chemiluminescence immunoassay (Elecsys, Roche Diagnostics, Basel,
Switzerland) at the Department of Clinical Chemistry, Akershus Univer-
sity Hospital, Lorenskog, Norway.
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2.6. Statistical analysis
Continuous variables were summarized by means and standard de-
viations (approximately normally distributed variables) and medians
and interquartile ranges (IQR) (non-normally distributed variables),
whereas categorical variables were presented by frequencies and corre-
sponding percentages. Group-wise comparisons were performed using
independent samples t-test, one-way analysis of variance (ANOVA),
Mann–Whitney U test, Kruskal–Wallis test, and Pearson's χ2-test or
Fisher's exact test (depending on cell frequencies), and correlations be-
tween LV measurements and diastolic function were tested with
Pearson's productmoment correlation (r) or Kendall's tau-b (τ). The as-
sociations between LVMI (and RWT) and various risk factors were
assessed by multivariable linear regression. The associations between
LVH (including subtypes of LV geometric pattern) and risk factors
were assessed by binary logistic regression. In order to deﬁne potential
explanatory variables for LVMI and LVH, univariable regressions were
applied on the following demographic and clinical variables: age, sex,
smoking status, body mass index (BMI), waist circumference, systolic
blood pressure (SBP), pulse rate, FPG category, total cholesterol, low-
density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL)
cholesterol, triglycerides, and NT-proBNP. HDL cholesterol, triglycer-
ides, and NT-proBNP were moderately to highly positively skewed
and therefore natural log-transformed before inclusion into the regres-
sion models. Statistically (on univariable analyses) and clinically signif-
icant variableswere included in the ﬁnalmultivariable linear and binary
logistic regression models, and stepwise backward selection was ap-
plied for adjustment of these models with a stay signiﬁcance level of
0.20. The signiﬁcance level for the univariable analyseswas 0.05. All sta-
tistical analyses were carried out using IBM SPSS Statistics 22 (IBM,
Armonk, New York, USA) and Stata/IC 13 (StataCorp LP, College Station,
Texas, USA).
3. Results
3.1. Characteristics of the study population
After applying the aforementioned exclusion criteria, a study cohort
of 693 subjects (486men and 207women) was left for analysis (Fig. 1),
including 346 individualswithNFG, 242with IFG, and 105with untreat-
ed DM. Subjects were middle-aged or elderly with a median age of 66
(IQR 60-70) years and mildly hypertensive with a mean systolic blood
pressure of 147 +/− 20 mm Hg. Mean BMI was 23.9 +/− 3.2 kg/m2,
and values of total and LDL cholesterol were 5.9 +/− 1.0 mmol/L and
3.9 +/− 0.9 mmol/L, respectively. Mean LVMI was 86 +/− 21 g/m2
(88 +/− 22 for men, 80 +/− 17 for women), and 13% (10% men, 19%
women) fulﬁlled the gender-speciﬁc criteria for LVH (6% eccentric and
7% concentric, respectively). Moreover, 18% (when excluding the 29
subjects with undetermined diastolic dysfunction) had grade 2 or 3
diastolic dysfunction. As shown in Table 2a, higher FPG categorywas as-
sociated with higher BMI, waist circumference, SBP, pulse rate, triglyc-
erides, LVM, and lower HDL cholesterol, whereas the presence of DM
was associated with greater values of IVS, PW, RWT, LVMI, male sex, a
greater prevalence of grade 2 or 3 diastolic dysfunction, and lower
values of LVEF. Table 2b shows the baseline characteristics of the sub-
jects categorized according to LV geometry.
3.2. Determinants of left ventricular mass
3.2.1. Determinants of left ventricular mass index
LVMI was signiﬁcantly higher in subjects with DM than those with-
out (90+/− 26 g/m2 vs. 85 +/− 20 g/m2, p = 0.01, independent sam-
ples t-test), but not signiﬁcantly different between subjects with IFG vs.
NFG (87+/− 21 g/m2 vs. 84+/− 19 g/m2, p=0.08, independent sam-
ples t-test). There was a weak, albeit signiﬁcant correlation between
LVMI and diastolic function (r= 0.171, p b 0.0001). In univariable anal-
yses, greater values of LVMIwere associatedwith higher age, BMI, waist
circumference, SBP, NT-proBNP, lower pulse rate, and male sex, but not
the graded FPG category. The adjusted multivariable linear regression
model is presented in Table 3a and included all these variables except
waist circumference. FPG categorywas forced into themodel and signif-
icantly interacted with the association between LVMI and NT-proBNP
(p b 0.0001). NT-proBNP was only signiﬁcantly associated with LVMI
in subjects with IFG or DM (Fig. 2a).
3.2.2. Determinants of left ventricular hypertrophy
Therewasno signiﬁcant difference in the prevalence of LVHbetween
subjects with DM and those without (14% vs. 12%, p= 0.6, Pearson's χ2-
test). There was a weak to moderate signiﬁcant correlation between
LVH and diastolic function (τ= 0.185, p b 0.0001). In univariable anal-
yses, the presence of LVHwas associatedwith higher age, BMI, SBP, HDL-
cholesterol, NT-proBNP, and female sex. The adjusted binary logistic re-
gression model is presented in Table 3b and included all of these vari-
ables except HDL-cholesterol, whereas FPG category was once again
forced into the model. FPG category also signiﬁcantly interacted with
the association between LVH and NT-proBNP (p = 0.01), and this asso-
ciation was stronger among subjects with IFG or DM (Fig. 2b).
3.3. Determinants of left ventricular geometry
3.3.1. Relative wall thickness
RWT was signiﬁcantly greater among patients with DM than sub-
jects without (0.43+/− 0.09 vs. 0.40+/− 0.08, p= 0.01, independent
samples t-test), but there was no difference between subjects with IFG
vs. NFG (0.40+/− 0.09 vs. 0.40 vs. 0.08, p=0.99, independent samples
t-test). RWT correlated weakly to moderately with diastolic function
(r = 0.259, p b 0.0001). The multivariable model for RWT prediction
is shown in supplemental Table A and included age and BMI, while
sex and FPG category were forced into the model. DM, but not IFG,
remained signiﬁcantly associated with greater RWT values, when com-
pared to subjects with NFG. No signiﬁcant interactions were detected.
3.3.2. Concentric left ventricular remodeling
There was no signiﬁcant difference in the prevalence of concentric
remodeling between subjects with DM and those without (32% vs.
30%, p= 0.6, Pearson's χ2-test). There was a weak tomoderate, but sig-
niﬁcant correlation between concentric remodeling and diastolic func-
tion (τ = 0.174, p b 0.0001). The multivariable regression model is
presented in supplemental Table B. Concentric remodeling was associ-
ated with higher age and BMI. Sex and FPG category were forced into
the model. There was a signiﬁcant interaction between FPG category
and age in the prediction of concentric remodeling (p= 0.02) (supple-
mental Figure A).
Table 1
Scheme for grading diastolic dysfunction.
Grade 0 (normal) Grade 1 (mild) Grade 2 (moderate) Grade 3 (severe)
Septal é (cm/s) ≥8 b8 b8 b8
Lateral é (cm/s) ≥10 b10 b10 b10
E-wave DT (ms) 140–240 ≥240 140–240 b140
E/A 0.8–1.5 b0.8 0.8–1.5 N1.5
E/é b9 ≤12 ≥9 ≥13
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3.3.3. Eccentric left ventricular hypertrophy
No statistically signiﬁcant difference in eccentric LVH was found
among subjects with DM compared to those without (3% vs. 7%, p =
0.2, Fisher's exact test). Therewas aweak, but signiﬁcant correlation be-
tween the presence of eccentric LVH and diastolic function (τ= 0.145,
p= 0.002). Themultivariable model for the prediction of eccentric LVH
is shown in supplemental Table C and included BMI, NT-proBNP,
triglycerides, and female sex. Age and FPG category were forced into
the model. The latter signiﬁcantly interacted with the association be-
tween eccentric LVHandNT-proBNP (p=0.04) (supplemental Figure B).
3.3.4. Concentric left ventricular hypertrophy
Concentric LVH was signiﬁcantly more prevalent among subjects
with DM than those without (11% vs. 6%, p = 0.03, Pearson's χ2-test),
Fig. 1. Flowchart showing the selection of the study population.
Table 2a
Baseline characteristics according to fasting plasma glucose category.
Variable All subjects
(n = 693)
Normal fasting plasma glucose
(n = 346)
Impaired fasting plasma glucose
(n = 242)
Diabetes mellitus
(n = 105)
P-value for difference
between FPG categories
Male sex 486 (70%) 208 (60%) 195 (81%) 83 (79%) b0.0001a
Age (years) 66 (60–70) 67 (60–70) 64 (59–67) 65 (62–69) 0.002c
Active smoking 121 (17%) 54 (16%) 47 (19%) 20 (19%) 0.4a
BMI (kg/m2) 23.9 +/− 3.2 23.4 +/− 3.0 23.9 +/− 2.8 25.7 +/− 3.8 b0.0001b
Waist circumference (cm) 96 +/− 11 92 +/− 11 98 +/− 10 103 +/− 11 b0.0001b
Systolic blood pressure (mmHg) 147 +/− 20 143 +/− 18 150 +/− 21 155 +/− 23 b0.0001b
Pulse rate (beats per minute) 73 +/− 12 71 +/− 12 74 +/− 12 77 +/− 13 b0.0001b
FPG at ﬁrst visit (mmol/L) 6.1 (5.4–6.5) 5.4 (5.1–5.7) 6.3 (6.2–6.5) 8.1 (7.4–9.2) b0.0001c
Total cholesterol (mmol/L) 5.9 +/− 1.0 5.9 +/− 0.9 5.9 +/− 1.0 6.0 +/− 1.1 0.5b
LDL cholesterol (mmol/L) 3.9 +/− 0.9 3.9 +/− 0.9 3.9 +/− 0.9 4.0 +/− 1.0 0.5b
HDL cholesterol (mmol/L) 1.3 (1.1–1.6) 1.4 (1.2–1.7) 1.3 (1.0–1.5) 1.1 (0.9–1.3) b0.0001c
Triglycerides (mmol/L) 1.2 (0.8–1.2) 1.0 (0.8–1.4) 1.2 (0.9–1.6) 1.7 (1.2–2.3) b0.0001c
NT-proBNP (pmol/L) 8 (5-15) 10 (5-18) 7 (4-13) 9 (6-16) b0.0001c
EF (%) 62 +/− 6 62 +/− 6 61 +/− 5 61 +/− 5 0.02b
IVS (mm) 11 +/− 2 10 +/− 2 11 +/− 2 11 +/− 2 b0.001b
PW (mm) 9 +/− 1 9 +/− 1 9 +/− 2 10 +/− 2 b0.001b
LVID (mm) 47 +/− 5 46 +/− 5 48 +/− 5 47 +/− 5 0.04b
RWT 0.41 +/− 0.08 0.40 +/− 0.08 0.40 +/− 0.09 0.43 +/− 0.09 0.04b
LVM (g) 166 +/− 46 158 +/− 40 172 +/− 47 180 +/− 55 b0.0001b
LVMI (g/m2) 86 +/− 21 84 +/− 19 87 +/− 21 90 +/− 26 0.01b
LVH 88 (13%) 43 (12%) 30 (12%) 15 (14%) 0.9a
LV geometry
Normal 397 (57%) 195 (56%) 146 (60%) 56 (53%) 0.4a
Concentric remodeling 208 (30%) 108 (31%) 66 (27%) 34 (32%) 0.5a
Eccentric hypertrophy 42 (6%) 27 (8%) 12 (5%) 3 (3%) 0.1a
Concentric hypertrophy 46 (7%) 16 (5%) 18 (7%) 12 (11%) 0.04a
Diastolic dysfunction 116 (18%) 60 (19%) 29 (13%) 27 (26%) 0.01a
Categorical variables (male sex, active smoking, LVH, LV geometry, grade 2 or 3 diastolic dysfunction) are given as n (%), whereas continuous variables are given as mean +/− SD (ap-
proximately normally distributed variables, i.e. BMI, waist circumference, SBP, pulse rate, total cholesterol, LDL cholesterol, LVMI, EF, IVS, PW, LVID, RWT, LVM, and LVMI) or median
(IQR) (non-normally distributed variables, i.e. age, FPG, HDL cholesterol, triglycerides, and NT-proBNP).
a Pearson's χ2-test.
b One-way ANOVA.
c Kruskal–Wallis test.
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but there was no signiﬁcant difference between subjects with IFG and
those with NFG (7% vs. 5%, p = 0.3, Pearson's χ2-test). The presence of
concentric LVH correlated moderately to strongly with diastolic func-
tion (τ= 0.280, p b 0.0001). The multivariable model is presented in
supplemental Table D. Concentric LVH was associated with higher age,
BMI, SBP, and NT-proBNP. Sex and FPG category were forced into the
model; however, with both IFG andDMas borderline signiﬁcant predic-
tors of concentric LVH. Furthermore, FPG category signiﬁcantly
interacted with the association between concentric LVH and NT-
proBNP (p = 0.02) (supplemental Figure C).
4. Discussion
The main ﬁndings of our study were: 1) Signiﬁcantly greater LVMI,
RWT, and prevalence of concentric LVH among subjects with untreated
DM than those without; 2) signiﬁcant interactions, i.e. effect modiﬁca-
tions, between FPG category and the association between NT-proBNP
and LVMI and LVH (incl. eccentric and concentric LVH), respectively,
with higher NT-proBNP being predominantly associated with greater
LVMI or LVH among patients with IFG or DM.
4.1. Demographics and risk factors
Unadjusted mean values of LV cavity dimension and wall thickness
were within normal ranges according to ASE and EACVI [23]. Although
it remains controversial whether indexing for height, weight, or
BSA should be the preferred method, most large population studies
reporting LVM have indexed for BSA, prompting us to use this as our
indexing term as well. The reported prevalence of LVH detected by
echocardiography in the general population is 5–20% [2,27,28], whereas
in patients with established DM, prevalence estimates vary between 20
and 70% [3,29,30], depending primarily on age and the diagnostic
criteria used. Keeping inmind the exclusion of subjectswith known car-
diovascular disease and/or use of cardiovascular, anti-diabetic, or lipid-
lowering therapy in the present study, our demographicswere in agree-
ment with previous similar studies.
In individuals without overt cardiovascular comorbidities, greater
age, SBP, BMI, DM, and ethnicity have been identiﬁed as independent
risk factors for increased LVMI [8–17]. LVMI is also greater inmen, inde-
pendently of body size [23], and NT-proBNP levels are signiﬁcantly
higher among subjects with LVH than those without, after adjustment
for blood pressure [31]. Our resultswere compatible herewith, as higher
age, SBP, BMI, NT-proBNP, DM, andmale sex were all signiﬁcantly asso-
ciated with greater LVMI, at least on univariable analysis.
4.2. Left ventricular mass and relative wall thickness
The effect of categorized FPG or IFG per se on LVMafter covariate ad-
justment has been evaluated in two subsamples from the Strong Heart
Study. De Marco et al. [19] showed that obese adolescent and young
adult individuals with IFG or DM exhibited progressively higher LVMI
and RWT than subjects with NFG, whereas Capaldo et al. [32] found
greater LVMI and RWT in subjects, who had either isolated IFG or com-
bined IFG and IGT on an oral glucose tolerance test (OGTT). The odds of
LVH was signiﬁcantly greater among individuals with both IFG and IGT
than thosewith IFG only, and the differences weremore apparent in fe-
male subjects. Supportive of these ﬁndings, independent associations
between IGT and LV wall thickness and LVM were also demonstrated
Table 2b
Baseline characteristics according to LV geometric pattern.
Variable Normal geometry
(n = 397)
Concentric remodeling
(n = 208)
Eccentric LVH
(n = 42)
Concentric LVH
(n = 46)
P-value for difference
between FPG categories
Male sex 297 (75%) 140 (67%) 21 (50%) 28 (61%) 0.002a
Age (years) 63 (59–67) 67 (61–70) 67 (64–70) 70 (67–74) b0.0001c
Active smoking 71 (18%) 36 (17%) 5 (12%) 9 (20%) 0.8a
BMI (kg/m2) 23.5 +/− 2.9 24.3 +/− 3.3 24.6 +/− 4.1 25.3 +/− 3.6 0.0001b
Waist circumference (cm) 96 +/− 11 96 +/− 11 93 +/− 12 96 +/− 12 0.4b
Systolic blood pressure (mmHg) 146 +/− 21 146 +/− 18 152 +/− 20 157 +/− 22 0.001b
Pulse rate (beats per minute) 73 +/− 12 73 +/− 12 70 +/− 11 74 +/− 13 0.41b
FPG at ﬁrst visit (mmol/L) 6.1 (5.4–6.5) 5.9 (5.4–6.5) 5.9 (5.4–6.2) 6.4 (5.6–7.1) 0.04c
Total cholesterol (mmol/L) 5.9 +/− 1.0 5.9 +/− 1.0 6.1 +/− 1.0 6.0 +/− 1.0 0.4b
LDL cholesterol (mmol/L) 3.9 +/− 0.9 3.9 +/− 1.0 4.1 +/− 0.8 4.0 +/− 1.0 0.5b
HDL cholesterol (mmol/L) 1.3 (1.0–1.6) 1.3 (1.1–1.6) 1.4 (1.3–1.9) 1.3 (1.1–1.5) 0.02c
Triglycerides (mmol/L) 1.2 (0.8–1.7) 1.2 (0.9–1.7) 1.0 (0.8–1.1) 1.2 (0.9–1.5) 0.04c
NT-proBNP (pmol/L) 7 (4-13) 9 (5-15) 17 (7-29) 16 (8-32) b0.0001c
EF (%) 61 +/− 5 63 +/− 6 61 +/− 5 64 +/− 7 b0.001b
IVS (mm) 10 +/− 2 11 +/− 2 12 +/− 2 14 +/− 2 b0.0001b
PW (mm) 9 +/− 1 10 +/− 1 10 +/− 1 12 +/− 1 b0.0001b
LVID (mm) 48 +/− 4 43 +/− 4 52 +/− 4 47 +/− 5 b0.0001b
RWT 0.36 +/− 0.04 0.48 +/− 0.06 0.38 +/− 0.03 0.51 +/− 0.09 b0.0001b
LVM (g) 156 +/− 35 159 +/− 36 226 +/− 65 235 +/− 50 b0.0001b
LVMI (g/m2) 80 +/− 15 82 +/− 15 120 +/− 27 122 +/− 17 b0.0001b
Diastolic dysfunction 45 (12%) 42 (22%) 11 (28%) 18 (40%) b0.0001a
Categorical variables (male sex, active smoking, grade 2 or 3 diastolic dysfunction) are given as n (%), whereas continuous variables are given as mean +/− SD (approximately normally
distributed variables, i.e. BMI, waist circumference, SBP, pulse rate, total cholesterol, LDL cholesterol, LVMI, EF, IVS, PW, LVID, RWT, LVM, and LVMI) or median (IQR) (non-normally dis-
tributed variables, i.e. age, FPG, HDL cholesterol, triglycerides, and NT-proBNP).
a Pearson's χ2-test.
b One-way ANOVA.
c Kruskal–Wallis test.
Table 3a
Multivariable linear regression model for the prediction of LVMI (adjusted r2 = 0.204).
Risk factor Beta-coefﬁcient (β)
(95% CI)
P-value
Age (per year) 0.25 (−0.04 to 0.55) 0.1
Female sex −11.03 (−14.49 to−7.57) b 0.0001
Body mass index (per kg/m2) 0.91 (0.44 to 1.39) b 0.001
Systolic blood pressure (per mmHg) 0.20 (0.13 to 0.28) b 0.0001
Pulse rate (per min−1) −0.26 (−0.38 to−0.13) 0.0001
Log(NT-proBNP) (per log(pmol/L)) 5.59 (3.71 to 7.48) b 0.0001
Fasting plasma glucose (FPG) category
Normal fasting glucose (NFG) (reference)
Impaired fasting glucose (IFG) 1.94 (−1.34 to 5.23) 0.25
Diabetes mellitus (DM) 1.17 (−3.26 to 5.61) 0.6
Waist circumference was signiﬁcantly associated with LVMI in univariable analysis only.
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Fig. 2. a: Forest plot showing the interaction between FPG category and NT-proBNP in the prediction of LVMI. ES: estimate; CI: conﬁdence interval. b: Forest plot showing the interaction
between FPG category and NT-proBNP in the prediction of LVH. ES: estimate; CI: conﬁdence interval.
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in both the Strong Heart Study [20] and the FraminghamHeart Study [18],
with the relations in the latter being stronger for women than for men.
Contrary to the above, but concordant with the Multi-Ethnic Study of
Atherosclerosis [33], we were unable to detect a graded association be-
tween FPG category and LVMI, presence of LVH, or RWT. Additionally,
there was no signiﬁcant interaction between sex and FPG category.
There are, however, several potential explanations for these discrepan-
cies between studies. Firstly, although the risk of future development of
type 2 DM is the same for individuals with either isolated IFG or IGT, the
overlap between these categories is very limited. The prevalence of IGT
is higher in women than in men, whereas the converse is true for IFG;
and IGT is a stronger predictor of cardiovascular mortality than is IFG
[34]. Furthermore, the development of adverse myocardial changes
may require long-term exposition to elevated glucose levels, and the
time period of glucometabolic disturbances in the present cohort
would expectedly be short. Secondly, data from the Strong Heart Study
referred to a speciﬁc ethnic cohort, i.e. American Indians, which may
limit the generalizability to prediabetic individuals from different eth-
nicities. Thirdly, as discussed in the following section, the importance
of impaired glucose metabolism may decrease with age, and the sub-
jects in the present study were on average older than those examined
by De Marco et al. (14–39 years) and Capaldo et al. (46–65 years),
respectively.
4.3. Important interactions
FPG category signiﬁcantly interacted with the association between
age and the presence of concentric remodeling, i.e. higher age was pre-
dominantly associated with concentric remodeling in subjects without
DM. This may be explained by the Cardiovascular Continuum, i.e. the
concept that both physiological and pathological aging brought on by
cardiovascular risk factors, e.g. DM, result in similar disturbances in LV
structure and function [35–37]. Therefore, impaired glucose metabo-
lism can be considered an accelerator for physiological aging. Since
both age and impaired glucose metabolism are known risk factors for
concentric LV changes [14–16,18,20], one would expect the effect of
FPG category to be weaker in older subjects and vice versa. Supporting
this hypothesis, we found that when the study population was split ac-
cording to median age, the association between the presence of either
IFG or DM and concentric LV remodeling was stronger and primarily
positive in only the younger study subjects (odds ratio for younger
half: 1.56 (95% CI: 0.91 to 2.67), p = 0.11; odds ratio for older half:
0.77 (95% CI: 0.48 to 1.23), p = 0.28; p = 0.053 for interaction).
In addition, therewas a signiﬁcant interaction between FPG category
and NT-proBNP, i.e. higher NT-proBNP was predominantly associated
with greater LVMI and presence of LVH among subjects with IFG or
DM. This ﬁnding could be explained by the following observations:
1) Subjects with IFG and DM had greater BMI than subjects with NFG,
and there is a known inverse relationship between BMI and BNP,
which may further be augmented by the presence of DM and other
components of the metabolic syndrome [38,39]; 2) Subjects with
untreated DM, but not IFG, had greater LVMI, RWT, and worse diastolic
function, which are all associatedwith higher NT-proBNP [31,40–42]. In
other words, a plausible, although speculative interpretation may be
that the association between NT-proBNP and LV size merely appeared
stronger among subjects with IFG due to lower NT-proBNP, whereas
among subjects with untreated DM, the stronger association resulted
from both low circulating NT-proBNP levels and adverse LV changes.
In fact, increased production of natriuretic peptides may precede
echocardiographically silent structural and functional changes, and
these early alterations ofmyocardial composition in DMmight bemedi-
ated by changes in the coronary microcirculation, i.e. decreased coro-
nary ﬂow reserve, leading to cell injury and reactive ﬁbrosis [43–45].
4.4. Potential clinical implications
In the present study, DMwasmainly associatedwith concentric LVH
as well as diastolic dysfunction, and of all the LV geometric patterns,
concentric LVH displayed the strongest correlation with diastolic dys-
function. As previously mentioned, subjects with concentric LVH may
be at greater risk of morbidity and mortality than subjects with other
LV geometric patterns [5–7]. Moreover, antihypertensive treatment
for LVH regression seems less effective among patients with established
DM [46,47], and the role of tight glycemic control among patients with
type 2 DM remains unproven. Formation of advanced glycation end
products and their cross-linking with collagen in patients with DM
may perhaps account for this therapeutic failure [48]. Therefore, in
DM, the presence of LVH could possibly represent a more deleterious
formof LVH than seen in other conditions. Since the adversemyocardial
alterations in DMmight be consequences of prolonged exposure to hy-
perglycemia and/or obesity, the presence of IFGmay provide a window
of opportunity to prevent or reduce LVH and the associated diastolic
dysfunction by halting progression into overt DM.
4.5. Limitations
Despite the relatively high participation rate of 72% inMPP-RES, one
could still argue that the study subjects did not represent a truly random
population sample since peoplewho agree to take partmay be healthier
than the general population. The applicability of the results in females
may be limited by the fact that 70% of subjects in the present study
were male, and the generalizability to groups other than middle-aged
to elderly Caucasians is unknown as well. Furthermore, our exclusion
of more than half of the original study population in order to get a co-
hort of apparently healthy subjects in whom possible associations
were not affected by medication may have introduced a selection bias.
The subgroup division was mainly based on single FPG measurements.
The addition of an OGTT and/or HbA1c measurements would have
been desirable, as IGT and DM deﬁned by OGTT are more common
among women than men, whereas IFG is more common among men
[34], and HbA1c provides an estimate of the average glucose levels,
and perhaps sustained myocardial affection, over a 8–12 week period
[49]. The oversampling of subjects with either IFG or DMalso prevented
us from using FPG as a continuous variable.
Although 2D-guided linear LVmeasurements have adverse prognos-
tic value and are feasible, especially when studying large populations, a
number of potential limitations deservementioning [23]: Themethod is
based solely on basal dimensions and unable to accommodate for LV
shape and size changes that might occur along the long axis of the
chamber, and the formula for calculating LVM assumes normal LV ge-
ometry and cubes the linear measurements. Therefore, even small er-
rors or, for example, discrete upper septal thickening (DUST), which is
particularly common in elderly, hypertensive subjects [50], may signif-
icantly inﬂuence the calculated mass. We assumed; however, that ex-
cluding subjects with reduced LVEF ≤50% would largely account for
distorted LV geometry except DUST. Lastly, the cross-sectional nature
of our study prevents us from making ﬁnite inferences about causality,
Table 3b
Binary logistic regression model for the prediction of left ventricular hypertrophy
(pseudo-r2 = 0.126).
Risk factor Odds ratio (OR) (95% CI) P-value
Age (per year) 1.05 (0.999 to 1.11) 0.054
Female sex 1.46 (0.87 to 2.47) 0.15
Body mass index (per kg/m2) 1.08 (1.01 to 1.16) 0.04
Systolic blood pressure (per mmHg) 1.02 (1.004 to 1.03) 0.009
Log(NT-proBNP) (per log(pmol/L)) 1.88 (1.39 to 2.56) b 0.0001
Fasting plasma glucose (FPG) category
Normal fasting glucose (NFG) (reference)
Impaired fasting glucose (IFG) 1.26 (0.72 to 2.21) 0.4
Diabetes mellitus (DM) 0.86 (0.41 to 1.80) 0.7
Log(HDL-cholesterol) was signiﬁcantly associated with the presence of left ventricular
hypertrophy in univariable analysis only.
45M. Pareek et al. / IJC Metabolic & Endocrine 9 (2015) 39–47
including the inability to assess the impact of exposure duration, e.g. in-
cidentally discovered DM and hypertension, on outcome.
5. Conclusion
In conclusion, although apparently healthy, elderly subjectswith un-
treated DM had higher values of LVMI and a greater prevalence of con-
centric LVH, the associationswere not independent of other risk factors.
However, FPG category signiﬁcantly interacted positively with the asso-
ciation betweenNT-proBNP and LV size, with NT-proBNP predominant-
ly being associated with greater LV size in subjects with IFG or DM.
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